- $1.32bn
- $1.48bn
- $660.57m
- 82
- 53
- 47
- 64
Annual balance sheet for Neogenomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 296 | 515 | 438 | 415 | 387 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 108 | 114 | 122 | 131 | 151 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 449 | 682 | 605 | 597 | 596 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 132 | 212 | 199 | 184 | 174 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 988 | 1,870 | 1,740 | 1,681 | 1,638 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 73.2 | 87.2 | 89.9 | 96.3 | 301 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 294 | 762 | 742 | 740 | 736 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 694 | 1,108 | 998 | 942 | 902 |
Total Liabilities & Shareholders' Equity | 988 | 1,870 | 1,740 | 1,681 | 1,638 |
Total Common Shares Outstanding |